92847-34-2 Usage
General Description
Ethyl 2-(3-chlorophenyl)-2-cyanoacetate is a chemical compound with the molecular formula C11H10ClNO2. It is commonly used in the synthesis of various pharmaceutical and agrochemical products due to its versatile nature. The compound is a key intermediate in the production of several important molecules, and it is often utilized in organic synthesis to introduce the 3-chlorophenyl and cyano groups into larger molecular structures. Ethyl 2-(3-chlorophenyl)-2-cyanoacetate is a colorless liquid with a strong odor, and it must be handled with care due to its potential hazardous properties. Overall, this chemical plays a crucial role in the development of numerous important products and compounds across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 92847-34-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,8,4 and 7 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 92847-34:
(7*9)+(6*2)+(5*8)+(4*4)+(3*7)+(2*3)+(1*4)=162
162 % 10 = 2
So 92847-34-2 is a valid CAS Registry Number.
92847-34-2Relevant articles and documents
PYRAZOLOPYRIMIDINE DERIVATIVES
-
Page/Page column 126, (2017/11/10)
The present invention covers Pyrazolopyrimidine compounds of general formula (I), in which n, o, X, Y, R, Q, R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds u
OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS
-
Page/Page column 65, (2008/06/13)
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo [3.3.0] octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula (I).
